malnutrition and cachexia have increased perioperative morbidity, mortality, and cancer recurrence. [11] [12] [13] [14] [15] As such, we hypothesized that placement of enteral access in patients with esophageal cancer prior to neoadjuvant chemoradiation, especially in patients with a presenting symptom of dysphagia, is not necessary and provides no nutritional or oncologic benefit in this patient population.
Methods
The Institutional Review Board at the University of Florida approved all details of this study, and Health Insurance Portability and Accountability Act compliance for all protected patient information/ identifiers was used. Informed consent was waived under the University of Florida Institutional Review Board for this retrospective study. A retrospective database was created of patients undergoing esophagectomy for malignancy at the University of Florida from 2007 − 2014. Patients were identified by CPT code via the departmental billing office. Routine demographic, clinicopathologic, operative, and perioperative complication variables were collected from the electronic medical record. Patients underwent preoperative staging and treatment in accordance with National Comprehensive Cancer Network guidelines. 16 Those patients who received neoadjuvant chemoradiation comprised the study cohort, as these patients are at most risk for perioperative malnutrition 13 and to limit cohort heterogeneity.
Patients were subsequently stratified based on undergoing a procedure to potentially improve nutrition via enteral access prior to esophagectomy. Those patients who underwent endoscopic esophageal stent placement, gastrostomy (either endoscopic or surgical) or jejunostomy tube placement (either percutaneous or surgical) comprised the "Access Group." Patients who did not undergo such procedures prior to definitive esophagectomy comprised the "NoAccess Group."
Statistical analyses were performed utilizing Stata 13 software (StataCorp; College Station, TX). Identified patients were divided into 2 cohorts based on the receipt of preesophagectomy enteral access and summary statistics performed comparing the Access Group with the No-Access Group. Student t test and χ 2 test was used to compare continuous and categorical variables, respectively. Recurrence free survival (RFS) was defined as the period of time from esophagectomy to radiographic or endoscopic detection of malignancy, death secondary to esophageal malignancy, or last follow-up, at which point the data were censored. Overall survival (OS) was defined as the period of time from esophagectomy to all-cause death. The KaplanMeier log-rank method was used to estimate RFS and OS based on preesophagectomy enteral access. A 2-sided P value of .05 and a 95% confidence interval (CI) were used for all analyses.
Results

Cohorts and demographic information
A total of 156 patients were identified between 2007 − 2014 who underwent esophagectomy for malignancy. Because patients who undergo neoadjuvant chemoradiation have been shown to be at increased risk for malnutrition, 13 we specifically chose to investigate this population of patients (n = 99) as they theoretically stand to benefit the most from placement of enteral access prior to esophagectomy and also to control for patients with early stage cancer who are typically asymptomatic and diagnosed incidentally, which may lead to selection bias. Their clinical and demographic variables are presented in Table 1 .
Esophageal adenocarcinoma was the most common histology in the entire cohort (78.8%), followed by squamous cell carcinoma (19.2%), and other histology (2%). Of the identified patients, 99 (63.5%) received neoadjuvant chemoradiation with curative intent. Patients received 45 − 50.4 Gy external beam radiation per National Comprehensive Cancer Network recommendations, 16 with one patient receiving a boost to the primary tumor for a total radiation dose of 55 Gy. Concurrent chemotherapy administration consisted of carboplatin/paclitaxel (28.8%), cisplatin/5-fluoruracil (47.9%), or other (23.3%) and make up the entire study cohort. All patients completed planned preoperative chemoradiation and underwent surgical resection. Patients were divided into 2 cohorts based on the receipt of ancillary enteral access at the discretion of the treating physician. This included 32 jejunostomy tube placements (32.3%), 14 gastrostomy tubes (14.1%), 1 endoscopic esophageal stent placement (1%), 1 nasoenteric tube (1%), and 1 combination of the above (1%). There were no patients in the NoAccess Group who subsequently converted to needing enteral access at a later time prior to esophagectomy. The demographics of the entire cohort and the Access versus No-Access Group are presented in Table 1 , which demonstrated no statistically significant difference between the No-Access and Access cohorts. The majority of patients were male in both groups (70% vs 77.6%, respectively; P = .39) with a median age of 66.6 years vs 64.2 years, respectively (P = .37).
Perioperative comparison
The preoperative cancer staging for both cohorts was similar, with the majority of patients having a T3 primary tumor or positive nodal disease (N1; Table 1 ) as staged by endoscopic ultrasound or positron emission tomography computed tomography (PET-CT). Additionally, tumor location did not have an impact on the receipt of preoperative enteral access, as the primary tumor location (proximal, mid, or distal esophagus) was similar between groups (Table 1 , P = .7). All patients completed their neoadjuvant treatment and went on to receive definitive esophagectomy, with the vast majority undergoing esophagectomy <90 days from completion of treatment in the No-Access and Access cohorts (95.6% vs 97.4%, respectively; P = .66). Despite the additional planning time required for placement of enteral access, the mean duration of time from diagnosis to definitive esophagectomy in the No-Access group (128 days) was similar to the Access Group (136 days, P = .3), suggesting that establishing pretreatment enteral access does not significantly delay the receipt of neoadjuvant chemoradiation or surgery. Perioperative parameters including operative time, operative blood loss, and hospital duration of stay were similar between the 2 cohorts ( Table 2) . Of note, the overall complication rate for the entire cohort was 57.6% with a similar rate between the No-Access and Access Groups (51% vs 64%, respectively; P = . 19 ). In particular, there was no difference in pulmonary complications between the No-Access versus Access cohorts (20.4% vs 12%, respectively; P = .26), which included: pneumonia, reintubation, and intubation >48 hours postoperatively. Additionally, while the anastomotic leak rate, as demonstrated on imaging (upper gastrointestinal swallow study and/or CT esophagram) with/without clinical symptoms, was lower in the NoAccess Group (8.2%) versus the Access Group (22%), this was not statistically significant (P = .06). Given that other factors may play a role in anastomotic leak rates, there was no difference noted in anastomotic leak rates based on cervical versus thoracic anastomosis location (13.7% vs 19.2%, respectively; P = .5) or on operative approach (open 17.9% vs minimally invasive 12.3% vs hybrid/ converted 33.3%; P = .35). Furthermore, despite the theoretical risk of conduit ischemia and the potential for increased anastomotic leak rates with the presence of a gastrostomy tube, there was no difference in anastomotic leak rates in patients with preoperative gastrostomy tube (21.4%) versus other modalities of preoperative enteral access (22.2%, P = .95). Finally, the rates of 30-day postoperative readmission (22% vs 27%, P = .68) and postesophagectomy visit to the emergency room without readmission (6% vs 14%, P = .2) was similar between the No-Access and Access Groups, respectively. Additionally, specific tube-related visits to the emergency room (4.1% vs 4%) and hospital admissions (2% vs 0%) after esophagectomy were similar between the No-Access versus Access cohorts, respectively.
Nutritional Assessment and Parameters of Enteral Access
Because dysphagia is a subjective symptom but is used as an indicator of malnutrition secondary to perceived poor oral intake and subsequent referral for surgical enteral access, we sought to determine the association of dysphagia with placement of preesophagectomy enteral access and malnutrition. There was no difference in the subjective symptom of dysphagia between the NoAccess Group (n = 37, 75.6%) and Access Group (n = 43, 86%; P = .2) with a total of 81% in our study cohort reporting dysphagia, which was the primary indication for enteral access (Table 1) . Of the 7 patients who did not report dysphagia, only 1 had obstruction on endoscopy. Interestingly, excluding patients who received neoadjuvant treatment, only 51% of patients reported dysphagia. Of the patients in the No-Access Group, (48, 98%) had enteral access placed intraoperatively, at the time of definitive esophagectomy. Of the Access cohort, 47 (94%) had enteral access postesophagectomy. This included patients who retained their original jejunostomy tube or had their esophageal stent/gastrostomy tube converted to a feeding jejunostomy tube. Therefore, 3 patients (6%) in the Access cohort and 1 (2%) in the No-Access cohort subsequently had no additional enteral access after definitive esophagectomy.
The potential benefit of preesophagectomy enteral access was next evaluated by determining changes in weight and albumin during the time period encompassing the neoadjuvant therapy and esophagectomy (Table 3 ). The mean percent weight change during the period of 6 months preesophagectomy to 6 months postesophagectomy in the No-Access cohort and Access cohort was −15.2% (range −34.1 to 1.4) and −11% (range −44 to 5.3), respectively (P = .09; Fig 1) . Furthermore, there was no difference in the mean serum albumin levels immediately preesophagectomy in the NoAccess (4.04 gm/dL, range 3.3 − 6.4, standard deviation [SD] 0.55) versus Access Groups (3.87gm/dL, range 3.1 − 4.5, SD 0.36; P = .2). As this lack of difference may have been secondary to an actual improvement in albumin in the Access Group during the time of neoadjuvant chemoradiation and a resultant benefit of preesophagectomy enteral access, serum albumin approximately 3 months prior to esophagectomy was queried, which would include baseline albumin levels of patients in both cohorts prior to any treatment or enteral access placement. This baseline serum albumin was measured a median of 103 days and 105 days prior to esophagectomy in the No-Access and Access Group, respectively (P = .6). The mean serum albumin at this time was 3.96 gm/dL (range 2.7 − 4.7, SD 0.51) for the No-Access cohort and 3.91 gm/dL (range 2.5 − 4.6, SD 0.55) for the Access cohort (P = .65), demonstrating a similar nutritional status in both cohorts prior to the placement of * The "u" stage is based on endoscopic ultrasound staging for both T and N stage but not every patient was staged via endoscopic ultrasound, resulting in numbers that are less than the total cohort. Statistical analysis is between No-Access and Access cohorts. Statistical analysis is between No-Access and Access cohorts. MUST was used to evaluate the level of malnutrition in patients undergoing neoadjuvant chemoradiation for esophageal malignancy followed by definitive esophagectomy. The score is based on BMI (0 − 2 points), degree of weight loss in the preceding 3 − 6 months (0 − 2 points), and acute illness with predicted lack of oral intake for at least 5 days (2 points). The score translates to low risk (0), medium risk (1), and high risk (2) for malnutrition. Statistical analysis is between No-Access and Access cohorts. The subset of patients who presented with dysphagia (+Dysphagia) but without esophageal obstruction on endoscopy are further analyzed.
enteral access. Finally, the mean total duration of enteral access for the Access cohort was 190.6 days (22 − 563 days) while the groups were statistically similar in terms of the mean duration of enteral access postesophagectomy (No-Access versus Access: 82 vs 95 days, respectively; P = .7). Several clinical tools are available to assess for malnutrition with the Malnutrition Universal Screening Tool (MUST) being one of the most widely used. 17, 18 This tool has shown to be a reproducible screening tool, is simple to use, and utilizes readily available clinical data that includes body mass index (BMI; 0 − 2 points), change in weight (0 − 2 points), and acute illness with potential for no nutritional intake >5 days (2 points). 19 This tool was utilized to assess the risk of malnutrition in our 2 cohorts by scoring the BMI of each patient~4 months prior to esophagectomy and their weight change prior to surgery (Table 3) . According to MUST, the 2 points for no nutritional intake >5 days is reserved for those acutely ill (i.e., hospitalized patients) and that will remain nothing by mouth >5 days. As none of the patients in this study met these criteria, no points were given for this category. There was no statistical difference in MUST scores between the 2 cohorts (Table 3) , demonstrating a similar level of nutrition in the 2 cohorts. Interestingly, there was actually a greater proportion of patients in the No-Access Group (30.2%) who were scored as "high risk" for malnutrition than the Access Group (20.9%), although this was not statistically significant (P = .32).
Finally, although a greater proportion of the Access cohort had obstruction on endoscopy (defined as inability to pass a traditional endoscope or need for dilation in order to pass the endoscope) compared to the No-Access cohort (26% vs 6.1%, respectively; P = .007; Table 1 ), when comparing the subset of patients with dysphagia but without obstruction, there was still no difference in nutritional assessment or parameters of enteral access except for duration of feeding access postesophagectomy (Table 3 ). This suggests that dysphagia alone is not an indication alone for preoperative enteral access.
Cohort survival
Given that RFS and OS in various cancers has been associated with nutritional status, 11, 12, 14, 15, 20, 21 Kaplan-Meier logistic regression analysis was performed to determine if differences exist between the 2 patient cohorts in these regards (Fig 2) . The actual median RFS and OS of the entire study cohort was 8.8 (interquartile range [IQR] 16.4) and 15.1 months (IQR 28), respectively. The Kaplan-Meier estimated median RFS in the No-Access Group was similar to the Access Group (67.4 mo vs not reached, respectively; P = .47). Additionally, there was no statistically significant difference in median OS as well (33.6 mo vs 24.5 mo, respectively; P = .51).
Discussion
As cancer cachexia and cancer-related sarcopenia continue to play large roles in the perioperative morbidity of oncology patients, clinicians seek to identify these patients and optimize their nutrition through surgical means. Few malignancies epitomize this physiologic derangement and potential need for surgical nutritional access as much as esophageal cancer does. However, despite advanced disease and subjective dysphagia, we have shown that not all patients require such intervention as patients who undergo enteral access prior to neoadjuvant chemoradiation and esophagectomy fair no better or worse than those patients who have surgical enteral access placed at the time of their definitive esophagectomy. These data should thus give pause to the clinician referring patients for, or surgeon performing, procedures to establish ancillary enteral access in patients with esophageal cancer prior to neoadjuvant therapy.
Malnutrition in the perioperative period has been associated with inferior surgical outcomes in a variety of disciplines. 11, [22] [23] [24] [25] In particular for patients with malignancy, poor nutrition has been associated with not only increased rates of operative morbidity but also increased rates of cancer recurrence. 11, 12, 20, 21, 26 Much research has therefore focused on not only optimizing perioperative nutrition, but also identifying patients who are at increased risk for such malnutrition. 20, [26] [27] [28] It can be argued that malignancies of the aerodigestive system provide the most impact to nutrition in the acute period, and subsequently operative outcome, compared to malignancies of other systems. 22 This is true of cancers of the esophagus, in which the presenting symptom is often dysphagia. 29 It is this subjective complaint that is often the impetus for enteral access referral once a diagnosis of esophageal cancer is secured. However, there are limited data that placement of surgical enteral access in patients with esophageal cancer is required based on the symptom of dysphagia as their nutrition may not necessarily be impacted from this symptom alone. As such, we sought to evaluate this clinical conundrum as the desire to optimize nutrition, when optimization may not necessarily be needed, may be overshadowed by the need to refer the patient for preoperative chemoradiation as part of their treatment sequencing strategy.
2,3
The weight loss and malnutrition exhibited by patients with cancer may be an effect of the malignancy itself or a result of the treatment. 3 Given that some form of weight loss is present in 31 − 87% of patients with malignancy, 22 with gastrointestinal malignancies having the highest prevalence, interventions to limit this are warranted. A distinction must be made between malnutrition, which the National Institute for Clinical Excellence defines as a BMI <18.5 kg/m, 2 unintentional weight loss >10%, or a combination of the 2, 30 and cachexia, which is malnutrition with additional proinflammatory processes that produce metabolic derangements, loss of muscle mass, and production of acute phase reactants. 31, 32 In fact, several guidelines have been set forth to assist the clinician with the management of malnutrition and cachexia associated with cancer. 31, 33, 34 These guidelines offer grade A evidence, supported by at least 2 level I investigations, for enteral nutrition in patients with moderate to severe malnutrition via oral nutritional supplementation or tube feeding 7 − 14 days preoperatively. 31, 33 It is recommended that nutritional support via tube feeding should not routinely be used in patients undergoing major abdominal cancer operations. 33 Furthermore, during chemoradiation it is suggested that the use of intensive dietary advice and oral nutritional supplements be used to increase dietary intake and prevent treatment-related weight loss (Grade A) but that nutritional support via tube feeding is appropriate if patients will not be able to ingest food for a long period of time (Grade B; supported by one level I investigation). However, data exists that with preoperative chemoradiation in patients with esophageal cancer, symptomatic dysphagia improves to the point where the patient is able to tolerate a diet, as early as after the first cycle of treatment, 9, 10 thus obviating the need for enteral access with its potential complications. [4] [5] [6] Given the routine referral to place enteral access in patients with esophageal cancer or these patients already having undergone an enteral access procedure prior to their esophagectomy evaluation, we sought to determine the utility of enteral access prior to neoadjuvant chemoradiation for esophageal cancer and hypothesized that it would offer no nutritional or perioperative benefit. Our data demonstrate that this is indeed the case as there was no difference in nutritional status, weight loss, perioperative complication rates, or survival between those patients who underwent enteral access prior to neoadjuvant chemoradiation with subsequent esophagectomy and those who completed their neoadjuvant chemoradiation and underwent enteral access at the time of definitive esophagectomy. A gastrostomy tube was the modality of preoperative enteral access in 28% of our patients, which may raise the concern for compromise of the gastric conduit, especially when a percutaneous endoscopic gastrostomy is used. When placed by a surgeon, it was performed in the setting of a diagnostic laparoscopy and inserted along the lesser gastric curve to preserve as much gastric conduit as possible in order to allow for bolus tube feeds.
Given the theoretical risk of conduit-associated ischemia around the site of the gastrostomy and potential for anastomotic leak or need for alternative conduit in our cohort based on the presence of a percutaneous endoscopic gastrostomy, our data is in agreement with other groups which have demonstrated no adverse outcomes with the placement of a percutaneous gastrostomy tube as we did not note any compromise of a conduit nor difference in anastomotic leak rates based on the presence of a gastrostomy tube preoperatively. [35] [36] [37] We nevertheless feel that if bolus tube feeds are desired, potentially because of patient ease, that a laparoscopic-assisted gastrostomy tube is ideal so that it can be placed outside of the planned gastric conduit. It should be additionally noted, that while the difference in anastomotic leak rate was not statistically significant between groups (P = .06), the trend was for a lower leak rate in the No-Access Group, which may become apparent with a larger cohort size although similar studies also did not find a difference in postoperative complication rates.
38,39 While we and others have shown the that placement of a feeding jejunostomy tube is safe and feasible prior to neoadjuvant chemoradiation and subsequent esophagectomy, the need for this in all patients undergoing this treatment sequencing is likely not needed. 7, 8 This study is limited by its retrospective nature and heterogeneous collection of nutritional labs and patient weights, as this was not thoroughly recorded in all cases. Additionally, as this is a singlecenter study at a tertiary referral center for esophagectomy, we were somewhat limited with patients who received their neoadjuvant care, or long-term oncologic follow-up, with their community oncologist. This limited our ability to fully document recurrence patterns, as illustrated by the longer RFS versus OS in our calculations as we were able to accurately determine death but not necessarily recurrence. Additionally, our ability to ascertain specific reasons for enteral access prior to neoadjuvant chemoradiation and the consistency with which supplemental tube feeds were used was hampered by many patients coming from other institutions. Nevertheless, our data is consistent with others in the literature but offers additional insight into enteral access utilization and the lack of survival benefit with the addition of enteral access before beginning neoadjuvant treatment. 10, 38, 39 It may be argued that the lack of differences between the No-Access and Access cohorts is because the initial albumin levels were similar. However, this arguably represents the selection of patients who would be most suited to undergo neoadjuvant therapy and ultimately esophagectomy as demonstrated by the fact that every patient in both cohorts completed their entire treatment sequencing. Additionally, the fact that the albumin levels were similar begs the question as to whether the patients in the Access cohort even needed the enteral access prior to neoadjuvant therapy. Despite these limitations, the study is bolstered by its cohort size, evaluation of only patients who received neoadjuvant chemoradiation, and the utilization of the Malnutrition Universal Screening Tool to better assess patient malnutrition retrospectively, which interestingly actually showed a greater proportion of patients in the No-Access Group as having severe malnutrition albeit through a retrospective analysis.
In summary, while perioperative nutrition should be of paramount concern in patients with esophageal cancer who are about to embark on neoadjuvant chemoradiation and ultimately esophagectomy for potential cure, a distinction must be made by the clinician between malnutrition and cancer cachexia as treatment can be very different. While we do not disagree that those with cancer cachexia likely benefit from a more intensive nutritional supplementation as provided by surgical enteral access, 31, 33 those patients who present with malnutrition as evidenced by weight loss and coupled with subjective dysphagia likely are best served by referral to a dietician, nutrition education, and oral nutritional supplementation. Most patients with esophageal cancer report some dysphagia, including our study cohort for which this symptom was present in 81% of patients and even in the CALGB 9781 trial, grade 3 and 4 dysphagia was reported in 42.3% of patients. The fact that of the 57 patients who did not receive neoadjuvant therapy in our study 29 (51%) reported dysphagia yet only 5 underwent preesophagectomy enteral access (17%) demonstrates that there is a bias toward referral for enteral access in patients undergoing neoadjuvant treatment, likely from higher preoperative tumor staging and not necessarily malnutrition. As such, dysphagia alone should not be an indicator for surgical enteral access but reserved for patients with cancer cachexia or obvious obstruction on endoscopy. While we did not identify a delay in proceeding to neoadjuvant chemoradiation in our Access cohort, it is a theoretical risk and thus patients should proceed directly to multimodality treatment. Should the nutritional status of patients deteriorate while on therapy, a feeding jejunostomy tube is still a viable option while neoadjuvant chemoradiation is being completed. [40] [41] [42] [43] 
